The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia

By  

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1495-1499

Bentham Science Publishers

Access to resources Recommend Favorite

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

By  

Current Pharmaceutical Design, Vol. 24, Iss. 4, 2018-04 ,pp. : 442-450

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia: Focus on Therapeutic Implications

By Farnier Michel  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 3, 2011-06 ,pp. : 145-152

Adis International

Access to resources Recommend Favorite

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

By Abifadel Marianne   Pakradouni Jihane   Collin Matthieu   Samson-Bouma Marie-Elisabeth   Varret Mathilde   Rabès Jean-Pierre   Boileau Catherine  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 11, 2010-11 ,pp. : 1547-1571

Informa Healthcare

Access to resources Recommend Favorite

Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R)

By  

Current Medicinal Chemistry, Vol. 17, Iss. 20, 2010-07 ,pp. : 2168-2182

Bentham Science Publishers

Access to resources Recommend Favorite